TriangleHEALTH PROFESSIONAL · SOURCE READING
Pomalidomide
Source: Kaposi Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 7, 2025 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.
The U.S. Food and Drug Administration (FDA) approved pomalidomide for the treatment of KS in patients with and without HIV.
Evidence (pomalidomide):
A phase I/II study of pomalidomide included 28 patients with KS. Ten patients were HIV-positive and 18 patients were HIV-negative.[23]
Source links and citations
A phase I/II study of pomalidomide included 28 patients with KS. Ten patients were HIV-positive and 18 patients were HIV-negative.[23]
The overall response rate was 71%, and 80% among patients without HIV. The median PFS was 10 months.[23]
Source links and citations
A phase I/II study of pomalidomide included 28 patients with KS. Ten patients were HIV-positive and 18 patients were HIV-negative.[23]
Pomalidomide was generally well tolerated. Common adverse events included neutropenia, anemia, fatigue, constipation, and rash. There were few grade 3 events (neutropenia, infection, and edema).[24]
Source links and citations
Pomalidomide is teratogenic, prescribed through a Risk Evaluation and Mitigation Strategy (REMS) program, and it should be given with aspirin to mitigate venous thromboembolism risk.
Publication references
Read the original reference and check its publication notices.
Preserved source evidence · Not medical advice